471270-60-7 Usage
Description
2-(3-HYDROXYPROPYLAMINO)-6-(O-HYDROXYBENZYLAMINO)-9-ISOPROPYLPURINE, an analogue of Olomoucine, is a potent inhibitor of cyclin-dependent kinases (Cdk) 1 and 2, with IC50 values of 100 nm and 80 nm, respectively. It is characterized by its off-white solid appearance and exhibits antiproliferative and proapoptotic effects, making it a promising compound for various applications in the pharmaceutical and biotechnology industries.
Uses
Used in Pharmaceutical Industry:
2-(3-HYDROXYPROPYLAMINO)-6-(O-HYDROXYBENZYLAMINO)-9-ISOPROPYLPURINE is used as a potent inhibitor for Cdk 1 and Cdk 2 for its ability to inhibit the activity of these proteins, which play a crucial role in cell cycle regulation and are often dysregulated in cancer cells. This makes it a potential therapeutic agent for the treatment of various types of cancer.
Used in Biotechnology Industry:
2-(3-HYDROXYPROPYLAMINO)-6-(O-HYDROXYBENZYLAMINO)-9-ISOPROPYLPURINE is used as a research tool for studying the role of Cdk 1 and Cdk 2 in cell cycle regulation and their involvement in cancer development. Its antiproliferative and proapoptotic effects also make it a valuable compound for investigating the mechanisms underlying cell growth and death, which could lead to the development of novel therapeutic strategies for cancer treatment.
Used in Drug Development:
2-(3-HYDROXYPROPYLAMINO)-6-(O-HYDROXYBENZYLAMINO)-9-ISOPROPYLPURINE is used as a lead compound in the development of new drugs targeting Cdk 1 and Cdk 2, which could potentially offer more effective treatments for cancer patients with better safety profiles and fewer side effects compared to existing therapies.
Used in Drug Combination Strategies:
2-(3-HYDROXYPROPYLAMINO)-6-(O-HYDROXYBENZYLAMINO)-9-ISOPROPYLPURINE can be used in combination with other chemotherapeutic agents to enhance their efficacy and overcome drug resistance in cancer treatment. Its ability to induce cell cycle arrest and apoptosis may synergize with the effects of other drugs, leading to improved therapeutic outcomes for patients with advanced or refractory cancers.
Check Digit Verification of cas no
The CAS Registry Mumber 471270-60-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,7,1,2,7 and 0 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 471270-60:
(8*4)+(7*7)+(6*1)+(5*2)+(4*7)+(3*0)+(2*6)+(1*0)=137
137 % 10 = 7
So 471270-60-7 is a valid CAS Registry Number.
471270-60-7Relevant articles and documents
In vitro biotransformation of 2,6,9-trisubstituted purine-derived cyclin-dependent kinase inhibitor bohemine by mouse liver microsomes
Rypka,Vesely,Chmela,Riegrova,Cervenkova,Havliek,Lemr,Hanus,Cerny,Lukes,Michalikova
, p. 1017 - 1031 (2007/10/03)
1. Biotransformation pathways of the cyclin-dependent kinase inhibitor 6-benzylamino-2-(3-hydroxypropylamino)-9-isopropylpurine (bohemine) by mouse liver microsomes in vitro were investigated. 2. Metabolite profiles of [8-3H]-labelled bohemine were established by TLC/3H-autoradiography and enzymatic and MS analyses were used to elucidate the chemical structures of the metabolites. The structures of the main primary metabolites were confirmed by synthesis of authentic compounds. 3. A schema of the primary NADPH-dependent pathways has been proposed involving N2- and N9-dealkylation, N6-debenzylation, aromatic hydroxylation, and C2 side chain oxidation of bohemine. Three of the primary metabolites detected, 6-(benzylamino)-2-(3-hydroxypropylamino)purine (M4), 6-amino-2-(3-hydroxypropylamino)-9-isopropylpurine (M5) and 6-(4-hydroxybenzylamino)-2-(3-hydroxypropylamino)-9-isopropylpurine (M6), all retaining their parent primary hydroxyl group, were subsequently shown to be converted, by a liver cytosolic NAD+-dependent system, into their corresponding carboxylic acids. M6 was subject to microsomal glycosidations requiring UDP-sugar donors. NADPH-dependent conversion of M6 into M5 by microsomes was also demonstrated. 4. Cytochrome P450 (CYP) enzymes-selective inhibitors were used to identify CYPs involved in bohemine biotransformation. The findings suggested that CYP2a and CYP3a substantially contributed to the NADPH-dependent bohemine transformation in vitro. 5. The findings will facilitate experiments designed to dissect enzymatic systems catalysing clearance of C2,C6,N9-trisubstituted purine compounds from mammalian tissues.
